Aging
Navigate
Submit an Article
COVID-19Research Paper|Volume 12, Issue 12|pp 11224—11237

Treatment strategies of hospitalized patients with coronavirus disease-19

Yaxiong Huang1, Chunlin Cai1, Jinglei Zang2, Jun Xie1, Dan Xu1, Fang Zheng1, Tao Zhan1, Kang Huang1, Yikai Wang3, Xiao Wang4, Zhe-Yu Hu5, Yapeng Deng5, Yuanlin Xie1,6
  • 1The First Hospital of Changsha City, Changsha 410005, Hunan, China
  • 2Changsha Health Vocational College, Changsha 410100, Hunan, China
  • 3Emory University Rollins School of Public Heath, Atlanta, GA 30322, USA
  • 4ICF, 3 Corporate Square NE., Atlanta, GA 30329, USA
  • 5Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, China
  • 6The Forth Hospital of Changsha City, Changsha 410013, Hunan, China
* Equal contribution
Received: March 31, 2020Accepted: May 14, 2020Published: June 17, 2020
https://doi.org/10.18632/aging.103370

Copyright © 2020 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

With the outbreak of coronavirus disease-19 (COVID-19), Changsha faced an increasing burden of treating the Wuhan migrants and their infected patients. This study is a retrospective, single-center case series of the 238 consecutive hospitalized patients with confirmed COVID-19 at the First Hospital of Changsha city, China, from 01/21 to 02/14, 2020; the final date of follow-up was 02/27, 2020. Of 238 patients 43.7% visited Wuhan, 58.4% got in touch with Wuhan people, and 47.5% had contacted with diagnosed patients. 37.8% patients had family members infected. 190 cases had mild / general disease, and 48 cases had severe / critical disease. Compared to mild or general patients, more severe or critical patients visited Wuhan (59.6% vs 40.2%; P=0.02) and contacted with Wuhan people (74.5% vs 55.0%; P=0.02). All patients received antiviral treatment, including Lopinavir / Ritonavir (29.3%), Interferon (14.6%) and their combination (40.6%), Arbidol (6.7%), Xuebijing (7.1%) and Chloroquine phosphate (1.3%). Severe and critical patients received glucocorticoid, Gamma-globulin and oxygen inhalation. Some received mechanic ventilation support. As of 02/27, 161 patients discharged. The median length of hospital stay was 13 days. The 10-, 14-, 20- and 28-day discharge rate was 19.1%, 42.8%, 65.0% and 76.4%, respectively. No hospital-related transmission was observed.